LRT Capital Management LLC Boosts Stake in IDEXX Laboratories, Inc. $IDXX

LRT Capital Management LLC lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 78.4% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,119 shares of the company’s stock after purchasing an additional 931 shares during the quarter. LRT Capital Management LLC’s holdings in IDEXX Laboratories were worth $1,434,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the business. Elyxium Wealth LLC acquired a new stake in IDEXX Laboratories in the fourth quarter valued at approximately $3,666,459,000. Northwestern Mutual Wealth Management Co. increased its holdings in IDEXX Laboratories by 63,503.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,444,445 shares of the company’s stock worth $977,210,000 after acquiring an additional 1,442,174 shares in the last quarter. Norges Bank acquired a new position in IDEXX Laboratories during the fourth quarter worth $332,265,000. Arrowstreet Capital Limited Partnership lifted its holdings in IDEXX Laboratories by 197.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 550,368 shares of the company’s stock valued at $372,340,000 after purchasing an additional 365,274 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in shares of IDEXX Laboratories by 60.0% in the third quarter. JPMorgan Chase & Co. now owns 869,930 shares of the company’s stock valued at $555,802,000 after purchasing an additional 326,348 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Wall Street Zen upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. UBS Group cut their target price on IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research note on Tuesday, April 28th. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average price target of $751.00.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $560.88 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. IDEXX Laboratories, Inc. has a 1-year low of $506.91 and a 1-year high of $769.98. The stock has a market cap of $44.24 billion, a PE ratio of 41.30, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. The firm has a fifty day moving average price of $563.06 and a 200 day moving average price of $627.69.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the company posted $2.91 earnings per share. The business’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.